Nexam Chemical Holding AB (publ) Interim Report 1 January – 30 June 2026

Second-quarter sales rose 11% year over year, reaching the highest quarterly level in the company’s history, alongside the first positive EBIT in its history. Gross margin improved to 48% (+1pp vs. the same quarter of 2025). Performance Masterbatch sales increased 7% and Performance Chemicals grew 16%, supporting the margin and earnings inflection.

Analysis

This reads like an operating-leverage inflection, not just a top-line print. In specialty chemicals/masterbatch, a 1ppt gross-margin improvement on mid-teens growth can move EBIT disproportionately because fixed manufacturing, logistics, and SG&A absorption tend to dominate below the gross line. If this is the first profitable EBIT quarter, the market will likely re-rate the name from "turnaround" to "self-funding" only if the next 1-2 quarters show that margin is repeatable rather than mix-driven.

The second-order winner is likely the broader specialty/polymer-additives group, while commodity chemical peers with less pricing power are the natural relative losers. If the volume gain reflects customer restocking, then downstream packaging and plastics converters may be near a trough in inventory destocking; if it reflects true end-demand, then it supports a multi-quarter upgrade cycle for names with similar exposure. The key distinction is whether this came from price/mix or from unit growth — the former is stickier, the latter can reverse quickly.

The contrarian risk is that this is a classic "one good quarter" trap: favorable feedstock timing, low comparison, or temporary mix can make margins look durable when they are not. What matters next is free cash flow, working-capital intensity, and whether management raises full-year EBIT guidance. Falsifiers are simple: gross margin slipping back below the high-40s, EBIT reverting negative, or a weaker order book in the next print. Time horizon: headline reaction is days; confirmation risk sits over 1-3 months; durable rerating is 6-18 months only if cash conversion follows earnings.

Key Decisions for Investors

• No immediate outright long without the ticker and cash-flow details; treat this as a watch item until next-quarter guidance confirms EBIT durability.
• If liquid and publicly listed, start a small relative-value long AVNT / short LYB basket for 1-3 months: specialty/polymer-additives exposure should outperform commodity chemical beta if the margin inflection is real. Target 8-12% spread capture; exit if LYB pricing strengthens or AVNT margins roll over.
• Use XLB as a sector hedge rather than a direction bet: long the specific specialty-chemicals inflection name, short XLB, only after confirmation of positive EBIT and stable working capital. Risk/reward is best on a pullback rather than the first spike.
• Set a hard alert for the next quarterly print: if gross margin stays above ~47% and EBIT remains positive, the stock/basket can re-rate sharply; if not, fade the move and avoid chasing.
• If the company discloses strong operating cash flow, upgrade the thesis from turnaround to quality compounder; if cash conversion is weak, treat the EBIT inflection as potentially non-recurring and reduce exposure.